Ispire Technology, Inc. ISPR

LOS ANGELES, CA / ACCESS Newswire / September 9, 2026 / (Nasdaq:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8 am ET on Wednesday, September 16, 2026, to discuss the Company's financial results for its fiscal fourth quarter and full year ended June 30, 2026.To listen to the conference call, please dial in using the information below.

Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ: ISPR), today announced the appointment of Steven Przybyla as its President, effective immediately. Przybyla will also continue to serve as the Company's Chief Legal Officer and Secretary giving the Company a senior, U.S.-based executive who will speak directly to investors about both Ispire's regulatory strategy and its growth plan.

Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, announced that it has entered into a joint venture with Shandong Jincheng Pharmaceutical Group Co., Ltd. (SZSE: 300233) ("Jincheng Pharma"), a global pharmaceutical company, to manufacture and commercialize nicotine pouch products.

Download the Complete Report Here AIR Global PLC (Proposed Ticker: AIIR) Global Flavored Shisha Leader Scaling into Higher-Value, Device-Led Inhalation Platforms AIIR enters public markets as a scaled, cash-generative category leader, offering differentiated exposure to a stable, value-led consumption category with embedded upside from mix evolution. The business is anchored by Al Fakher, the largest […]

Moby summary of Ispire Technology Inc.'s Q3 2026 earnings call

Ispire Technology Inc. (ISPR) delivered earnings and revenue surprises of -750.00% and -17.32%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Ispire Technology Inc. (Nasdaq: ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the third quarter of fiscal 2026, for the three months ended March 31, 2026.